STOCK TITAN

Stoke Therapeutics (NASDAQ: STOK) CMO gets 10,000 shares, sells some for taxes

(Moderate)
(Negative)
Form Type
4

Rhea-AI Filing Summary

Stoke Therapeutics, Inc. (STOK) reported insider equity activity by its Chief Medical Officer, Barry Ticho. On August 14, 2026, he exercised 10,000 performance stock units, receiving 10,000 shares of common stock at a price of $0.00 per share. On August 18, 2026, the company facilitated issuer-mandated sales of 4,525 and 242 common shares, respectively, to satisfy tax withholding liabilities tied to restricted stock unit vesting, at weighted average prices around $32 per share across specified price ranges.

Positive

  • None.

Negative

  • None.
Insider Ticho Barry
Role CHIEF MEDICAL OFFICER
Sold 4,767 shs ($153K)
Approx. gross sale proceeds $153K
Type Security Shares Price Value
Sale Common Stock F1, F2 4,525 $32.0072 $145K
Sale Common Stock F1, F3 242 $32.4681 $8K
Exercise Performance Stock Units F4, F5 10,000 $0.00 $0.00
Exercise Common Stock 10,000 $0.00 $0.00
Holdings After Transaction: Performance Stock Units — 0 shares (Direct); Common Stock — 25,655 shares (Direct)
Footnotes (5)
  1. F1. The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
  2. F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.40 to $32.36 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
  3. F3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.44 to $32.54 per share, inclusive.
  4. F4. Each performance stock unit represents a right to receive one share of the Issuer's common stock.
  5. F5. Achievement of this performance stock unit award was certified on August 14, 2025. Pursuant to the terms of the award agreement between the reporting person and the Issuer, half the award vested on August 14, 2025 and the remainder vests on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date.
Shares sold (tax withholding) 4,525 shares Common stock sold on August 18, 2026 to satisfy tax withholding liabilities
Additional shares sold (tax withholding) 242 shares Common stock sold on August 18, 2026 to satisfy tax withholding liabilities
Weighted average sale price 1 $32.0072 per share Weighted average for sales between $31.40 and $32.36 per share
Price range 1 $31.40–$32.36 per share Range for the larger August 18, 2026 sale
Weighted average sale price 2 $32.4681 per share Weighted average for sales between $32.44 and $32.54 per share
Price range 2 $32.44–$32.54 per share Range for the smaller August 18, 2026 sale
Performance stock units exercised 10,000 units PSUs exercised on August 14, 2026 into common stock
Underlying common shares from PSUs 10,000 shares Each performance stock unit convertible into one share of common stock
performance stock unit financial
"Each performance stock unit represents a right to receive one share"
A performance stock unit is a type of reward companies give to employees, usually managers, that depends on how well the company performs over time. If the company hits specific goals, the employee earns shares of stock, like earning a prize for reaching certain levels in a game. It motivates employees to work hard because their rewards are tied to the company's success.
weighted average price financial
"The reported price in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
tax withholding liabilities financial
"sale to satisfy tax withholding liabilities in connection with the vesting"
restricted stock units financial
"in connection with the vesting and settlement of restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

FAQ

What insider transactions did STOK’s Chief Medical Officer report on this Form 4?

Barry Ticho reported exercising 10,000 performance stock units into common stock and issuer-mandated sales of 4,525 and 242 shares to cover tax withholding liabilities related to restricted stock unit vesting.

How many Stoke Therapeutics (STOK) shares were sold in the tax withholding transactions?

A total of 4,767 common shares of STOK (4,525 + 242) were sold. These sales were described as issuer-mandated to satisfy tax withholding liabilities from restricted stock unit vesting, rather than discretionary open-market sales.

At what prices were the STOK shares sold by the Chief Medical Officer?

The reported prices are weighted averages. One sale averaged $32.0072 per share across trades ranging from $31.40–$32.36, and the other averaged $32.4681 across trades ranging from $32.44–$32.54 per share.

What did the 10,000 performance stock units convert into for STOK’s CMO?

Each performance stock unit represented a right to receive one share of common stock, so 10,000 PSUs converted into 10,000 shares of Stoke Therapeutics common stock at an effective exercise price of $0.00 per share.

Were the STOK insider share sales under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked as being under a plan. Instead, a footnote explains the sales were issuer-mandated to cover tax withholding liabilities arising from restricted stock unit vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ticho Barry

(Last)(First)(Middle)
C/O STOKE THERAPEUTICS, INC.
45 WIGGINS AVENUE

(Street)
BEDFORD MASSACHUSETTS 01730

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CHIEF MEDICAL OFFICER
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/14/2026M10,000A$030,422D
Common Stock08/18/2026S(1)4,525D$32.0072(2)25,897D
Common Stock08/18/2026S(1)242D$32.4681(3)25,655D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Performance Stock Units(4)08/14/2026M10,000 (5)08/14/2026Common Stock10,000$00D
Explanation of Responses:
1. The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.40 to $32.36 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.44 to $32.54 per share, inclusive.
4. Each performance stock unit represents a right to receive one share of the Issuer's common stock.
5. Achievement of this performance stock unit award was certified on August 14, 2025. Pursuant to the terms of the award agreement between the reporting person and the Issuer, half the award vested on August 14, 2025 and the remainder vests on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date.
/s/ Jonathan Allan, Attorney-in-Fact08/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)